Published in BMJ on March 01, 2012
Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women. Am J Epidemiol (2013) 1.56
A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev (2013) 1.08
Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One (2013) 0.99
Screening for cervical cancer using automated analysis of PAP-smears. Comput Math Methods Med (2014) 0.96
Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy (2015) 0.95
Does social disadvantage affect the validity of self-report for cervical cancer screening? Int J Womens Health (2013) 0.95
Malignant tumors of the female reproductive system. Saf Health Work (2012) 0.90
The Clinical Role of HPV Testing in Primary and Secondary Cervical Cancer Screening. Obstet Gynecol Int (2013) 0.88
Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol (2014) 0.84
The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS One (2015) 0.83
Cervical screening and cervical cancer death among older women: a population-based, case-control study. Am J Epidemiol (2014) 0.81
Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? Int J Cancer (2016) 0.79
Cervical Cancer Screening: Defining the Need for Research. Geburtshilfe Frauenheilkd (2013) 0.78
Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program. BMC Cancer (2016) 0.78
Effect of screening on deaths from cervical cancer in Sweden. BMJ (2012) 0.77
Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer (2016) 0.77
Distribution of Carcinogenic Human Papillomavirus Genotypes and Association to Cervical Lesions among Women in Fez (Morocco). PLoS One (2016) 0.77
CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer. PLoS One (2015) 0.77
Social, demographic and healthcare factors associated with stage at diagnosis of cervical cancer: cross-sectional study in a tertiary hospital in Northern Uganda. BMJ Open (2016) 0.76
Cervical and breast cancer screening participation for women with chronic conditions in France: results from a national health survey. BMC Cancer (2016) 0.75
Effect of pay-for-performance on cervical cancer screening participation in France. Int J Health Econ Manag (2016) 0.75
Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009-2014. J Gynecol Oncol (2017) 0.75
Regulatory roles of miRNA-758 and matrix extracellular phosphoglycoprotein in cervical cancer. Exp Ther Med (2017) 0.75
Overdiagnosis in cancer. J Natl Cancer Inst (2010) 10.31
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
Randomised prostate cancer screening trial: 20 year follow-up. BMJ (2011) 6.50
Interpreting trends in cancer patient survival. J Intern Med (2006) 5.61
Uses and abuses of screening tests. Lancet (2002) 3.96
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst (2008) 3.24
Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ (2009) 3.20
Socio-economic inequalities in breast and cervical cancer screening practices in Europe: influence of the type of screening program. Int J Epidemiol (2010) 2.69
Barriers to cervical cancer screening attendance in England: a population-based survey. J Med Screen (2009) 2.55
FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol (1994) 2.10
Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol (1999) 1.91
Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med (1999) 1.82
History of the FIGO cancer staging system. Int J Gynaecol Obstet (2008) 1.81
Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer (2009) 1.80
The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer (2009) 1.56
Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics (2006) 1.27
The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol (1995) 1.27
Improved control of invasive cervical cancer in Sweden over six decades by earlier clinical detection and better treatment. J Clin Oncol (1995) 1.11
Reasons for non-attendance at cervical screening as reported by non-attendees in Sweden. J Psychosom Obstet Gynaecol (2008) 1.10
Cervical screening participation and risk among Swedish-born and immigrant women in Sweden. Int J Cancer (2011) 1.08
Cancer screening: the clash of science and intuition. Annu Rev Med (2009) 1.07
Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of The Netherlands, 1992-2001. Eur J Obstet Gynecol Reprod Biol (2008) 1.05
Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer (1995) 1.03
Factors related to participation in a cervical cancer screening programme in urban Sweden. Eur J Cancer Prev (2005) 1.02
How do women who choose not to participate in population-based cervical cancer screening reason about their decision? Psychooncology (2008) 1.01
Routine audit of large-scale cervical cancer screening programs. J Natl Cancer Inst (2008) 0.98
Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry. Int J Cancer (2007) 0.90
Age of diagnosis of squamous cell cervical carcinoma and early sexual experience. Cancer Epidemiol Biomarkers Prev (2009) 0.90
Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. Am J Obstet Gynecol (2009) 0.85
Screening history of women with invasive cervical cancer in north-east Italy. Eur J Obstet Gynecol Reprod Biol (2010) 0.84
Survival from cancer of the uterine cervix in England and Wales up to 2001. Br J Cancer (2008) 0.83
Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med (2009) 7.24
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med (2004) 5.67
Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ (2010) 5.60
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med (2007) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer (2009) 4.50
Should donors be allowed to give broad consent to future biobank research? Lancet Oncol (2006) 4.30
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med (2012) 3.56
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst (2008) 3.24
Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst (2004) 3.20
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
Ethical framework for previously collected biobank samples. Nat Biotechnol (2007) 2.81
Perinatal risk factors for infantile autism. Epidemiology (2002) 2.77
Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ (2008) 2.63
Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol (2009) 2.59
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Seroepidemiology of the human polyomaviruses. J Gen Virol (2003) 2.32
2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol (2012) 2.32
Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst (2009) 2.32
Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet (2003) 2.27
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ (2014) 2.27
Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Med Res Methodol (2007) 2.13
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol (2007) 2.09
Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst (2013) 1.99
Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ (2007) 1.97
Familial aggregation of amyotrophic lateral sclerosis. Ann Neurol (2009) 1.86
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Global proficiency study of human papillomavirus genotyping. J Clin Microbiol (2010) 1.78
A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004. Gut (2011) 1.70
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med (2008) 1.65
Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol (2008) 1.62
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood (2008) 1.61
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol (2002) 1.56
Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis (2007) 1.54
Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol (2006) 1.53
Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol (2007) 1.51
Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med (2009) 1.48
High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors. J Invest Dermatol (2004) 1.48
A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res (2004) 1.47
Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Västerbotten County, Sweden. J Med Virol (2006) 1.47
A pooled analysis of interval cancer rates in six European countries. Eur J Cancer Prev (2010) 1.46
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol (2012) 1.46
Risk of oral clefts in relation to prepregnancy weight change and interpregnancy interval. Am J Epidemiol (2008) 1.44
Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch Neurol (2009) 1.44
A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology (2013) 1.44
A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer (2002) 1.43
A general framework for parametric survival analysis. Stat Med (2014) 1.43
Cholangiocarcinoma among workers in the printing industry: using the NOCCA database to elucidate the generalisability of a cluster report from Japan. Occup Environ Med (2013) 1.42
Can association between preterm birth and autism be explained by maternal or neonatal morbidity? Pediatrics (2009) 1.41
The impact of plasma preparations and their storage time on short-term posttransfusion mortality: a population-based study using the Scandinavian Donation and Transfusion database. J Trauma Acute Care Surg (2012) 1.41
Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med (2007) 1.40
Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol (2009) 1.40
Effect of NHS walk-in centre on local primary healthcare services: before and after observational study. BMJ (2003) 1.40
Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer (2005) 1.39
[In Process Citation]. Lakartidningen (2015) 1.38
Evidence-based sample size calculations based upon updated meta-analysis. Stat Med (2007) 1.35
Choosing the relative survival method for cancer survival estimation. Eur J Cancer (2011) 1.34
Determinants of successful implementation of population-based cancer screening programmes. Eur J Cancer (2011) 1.33
Cancer incidence among firefighters: 45 years of follow-up in five Nordic countries. Occup Environ Med (2014) 1.33
Attitudes to HPV vaccination among parents of children aged 12-15 years-a population-based survey in Sweden. Int J Cancer (2010) 1.32
Metagenomic sequencing of "HPV-negative" condylomas detects novel putative HPV types. Virology (2013) 1.27
Colorectal cancer survival in socioeconomic groups in England: variation is mainly in the short term after diagnosis. Eur J Cancer (2011) 1.27
Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med (2009) 1.26
Assessing quality and functionality of DNA from fresh and archival dried blood spots and recommendations for quality control guidelines. Clin Chem (2007) 1.26
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol (2012) 1.24
Estimating net survival in population-based cancer studies. Int J Cancer (2013) 1.24
A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.23
Meta-analysis of heterogeneously reported trials assessing change from baseline. Stat Med (2005) 1.23
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol (2003) 1.20
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 1.19
Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol (2005) 1.18